

## **VEDOLIZUMAB**

(Entyvio)

## **Order Form**

**Outpatient Infusion** 

| Patient Name  |   |             |  |
|---|---|-------------|--|
| DOB   |   |             |  |
| Address   |   |             |  |
| Phone   |   |             |  |
|   |   |             |  |
| Order Status   □   New Order   □   Renewal  |   | Renewal     | <ul> <li>Dose or Frequency Change</li> </ul> |
| Allergies:  |   |             | Weight:<br>Height:                           |
| Diagnosis   | <ul><li>□ Crohn's Disease</li><li>□ Ulcerative Colitis</li><li>Other:</li></ul> |             | Diagnosis Code:                              |
| Required<br>Information   | Negative Quantiferon TB, T-spot or chest x-ray (no active disease)              |             | Date:  |
|   | Diagnostic Hepatitis B panel  |             | Date:  |
|   | Coccidioides Screen/Panel   |             | Date:  |
|   | CBC and CMP   |             | Date:  |
| Required Documentation  H&P or progress note supporting diagnosis  Medication history Recent labs (as above) and/or diagnostic test results |   |             |  |
| Labs  | ☐ Hepatic Function panel every 3 months   | 5           | ☐ Other:                                     |
| Pre-Medications  □ Diphenhydramine ○ PO ○ 25 mg □ Acetaminophen ○ 325 mg ○ IV ○ 50 mg ○ 650 mg □ Other:                                     |   |             |  |
| Entyvio (vedolizumab) IV Medication Order   |   |             |  |
| Entyvio (vedolizumab) IV 300 mg Induction: Week 0, 2, 6, then every weeks thereafter Maintenance: Every weeks Other:                        |   |             |  |
| Infusion Reaction Medications Hypersensitivity Reaction Protocol will be utilized unless otherwise specified                                |   |             |  |
| Provider (print name): Date:  |   | Pate:       |  |
| Provider Signature:   |   | NPI:        |  |
| Office Phone:   |   | Office Fax: |  |